KD025: Phase IIa started

Kadmon began an open-label, U.S. Phase IIa trial to evaluate 200 and 400 mg KD025 once daily and 200 mg KD025 twice daily for 24 weeks in about 48 patients who have received an allogeneic bone marrow ...